QY201 / E-nitiate Biopharma - LARVOL DELTA

The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects. (PubMed, J Clin Pharmacol) - "QY201 was generally safe and well tolerated following oral administration, with dose-limiting toxicity of the highest tested dose of 40 mg being well tolerated. The favorable PK, PD, safety, and tolerability results from these studies supported evaluations of QY201 in future clinical trials."

Clinical • Journal • PK/PD data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • CRP • JAK1 • TYK2

QY201 in adults with moderate-to-severe atopic dermatitis: 12-week results from a dose-finding phase 2 trial (AAD 2025) - No abstract available

Clinical • Late-breaking abstract • P2 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P1/2 | N=260 | Not yet recruiting | Sponsor: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

New P1/2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology